5-Loxin reduces knee pain and improves the ability to walk in patients with painful arthritis of the knee

5-Loxin is a derivative of the herb Boswellia serrata that is rich in Boswellia’s most active component known as AKBA; it is 30% AKBA. Boswellia has known anti-inflammatory activity that is due to its ability to inhibit the body’s inflammatory component known as the 5-lipoxygenase enzyme. 
In this 90 day double-blinded, randomized clinical trial, 75 patients with painful arthritis of the knee were placed on 5-Loxin or on placebo. The patients received either 100mg or 250mg of 5-Loxin or placebo per day. Each patient was individually evaluated for pain and physical function 5 times over the course of the study. At the end of the 90 day clinical trial both dosages of 5-Loxin gave clinically and statistically significant improvements in pain reduction and the ability to function. Samples of the synovial fluid show that 5-Loxin decreased the level of the MMP-3 enzyme in the joint fluid samples. The MMP-3 enzyme degrades the cartilage in the knee joint. The 5-Loxin was comparable to placebo in safety.  

5-Loxin reduced pain and improved the ability to use the knee while protecting the joint by lowering the level of the cartilage destroying enzyme MMP-3. The study is published online ahead of print in the journal Arthritis Research and Therapeutics.